IMMNOS Stock Overview
A diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Immunovia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 34.30 |
| 52 Week High | SEK 63.05 |
| 52 Week Low | SEK 30.28 |
| Beta | 1.41 |
| 1 Month Change | 0% |
| 3 Month Change | -4.08% |
| 1 Year Change | -44.68% |
| 3 Year Change | -79.87% |
| 5 Year Change | n/a |
| Change since IPO | -77.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMMNOS | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.5% | -2.6% |
| 1Y | -44.7% | -10.6% | 2.4% |
Return vs Industry: IMMNOS underperformed the UK Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: IMMNOS underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| IMMNOS volatility | |
|---|---|
| IMMNOS Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: IMMNOS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IMMNOS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 64 | Philipp Mathieu | www.immunovia.com |
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company’s product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer.
Immunovia AB (publ) Fundamentals Summary
| IMMNOS fundamental statistics | |
|---|---|
| Market cap | SEK 551.76m |
| Earnings (TTM) | -SEK 147.90m |
| Revenue (TTM) | SEK 949.00k |
581.4x
P/S Ratio-3.7x
P/E RatioIs IMMNOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMNOS income statement (TTM) | |
|---|---|
| Revenue | SEK 949.00k |
| Cost of Revenue | SEK 4.15m |
| Gross Profit | -SEK 3.20m |
| Other Expenses | SEK 144.70m |
| Earnings | -SEK 147.90m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 09, 2023
| Earnings per share (EPS) | -6.54 |
| Gross Margin | -336.78% |
| Net Profit Margin | -15,584.62% |
| Debt/Equity Ratio | 0% |
How did IMMNOS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/28 06:54 |
| End of Day Share Price | 2022/10/31 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immunovia AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Juan Pedro Rodríguez Serrate | Edison Investment Research |
| Alexandru Cogut | Kempen & Co. NV |